bioRxivGenomicsPreprint
Mapping kinase-dependent tumor immune adaptation with multiplexed single-cell CRISPR screens
Lingting ShiiD, Ross M. GiglioiD, Qingyuan CaiiD, Mathini VaikunthaniD, Justin HongiD, Abdullah Naqvi, Marina Milea, Hannah Khanshali, Anna Schoonen, Nicholas Y. Hou, Jonathan GuoiD, Melanie Fraidenburg, Xumin SheniD, Seth W. MalinowskiiD, Keith Lloyd LigoniD, Raul RabadaniD, Elham AziziiD, José L. McFaline‐FigueroaiD
Abstract
Immune dysfunction in cancer is enacted by multiple programs, including tumor cell-intrinsic responses to distinct immune subpopulations. A subset of these immune evasion programs can be systematically recapitulated through direct tumor-immune interactions in vitro. Here, we present an integrated, high-throughput single-cell CRISPR screening framework focused on the protein kinome for mapping the tumor-intrinsic regulation of T cell-driven immune pressure in glioblastoma (GBM). We combine pooled CRISPR interference and activation (CRISPRi/a) with immune-matched NY-ESO-1 antigen-specific allogeneic GBM-T cell co-culture and massively multiplexed single-cell transcriptomics to systematically quantify how genetic perturbation reshapes baseline tumor state and adaptive responses across graded effector-to-target ratios. We further leverage deep generative models for analyzing pooled CRISPR screens to decipher the effects of genetic perturbations on the mechanisms of tumor resistance. This framework resolves distinct modules of immune evasion and survival, including the regulation of the antigen-presentation machinery, interferon/NF-{kappa}B signaling, oxidative stress resilience, and checkpoint/cytokine programs, while identifying perturbations that reroute the continuous tumor transcriptional trajectory induced by T cell engagement. A secondary chemical screen in patient-derived GBM cultures identified putative kinase targets of immune evasion phenotypes (e.g., EPHA2 and PDGFRA), whose inhibition leads to the blockade of evasive programs and enhances T cell-mediated GBM killing. Together, this workflow provides a scalable blueprint for comprehensive charting of the genetic control of tumor-immune interactions.
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Double knockout CRISPR screen in cancer resistance to T cell cytotoxicity
Jonathan Joon-Young Park, Adan Codina, … Sidi Chen·Journal of Hematology & OncologyPeer-reviewed·Dec 1, 2022
- MAPK/ERK signaling in gliomas modulates interferon responses, T cell recruitment, enhances tumor-microglia crosstalk, and drives immune checkpoint blockade efficacy.
Kwang‐Soo Kim, Junyi Zhang, … Adam M. Sonabend·Nature CommunicationsPeer-reviewed·Jun 25, 2026
- In vivo genome-wide CRISPR screens in human T cells to enhance T cell therapy for solid tumors
Qi Liu, Peixin Amy Chen, … Julia C. Carnevale·bioRxiv·Sep 23, 2025
- Genome-wide profiling of druggable active tumor defense mechanisms to enhance cancer immunotherapy
R. J. Kishton, S. J. Patel, … N. P. Restifo·bioRxiv·Nov 18, 2019
- Single-cell genetic heterogeneity linked to immune infiltration in glioblastoma.
K. A. Walentynowicz, D. Engelhardt, … M. Janiszewska·bioRxiv·Sep 20, 2021
- STING activation counters glioblastoma by vascular alteration and immune surveillance
J. V. Joseph, M. S. Blaavand, … M. K. Thomsen·bioRxiv·Sep 3, 2023